Health Care · Surgical & Medical Instruments & Apparatus

UFPT UFP TECHNOLOGIES INC SEC Filings & Insider Trading Activity 2026

company
CIK 914156151 filings
Russell 2000

UFPT at a glance

UFP TECHNOLOGIES INC (UFPT, SEC CIK 914156) filed its latest 10-K annual report on February 27, 2026, a 10-Q quarterly report on November 6, 2026, an 8-K current report on November 3, 2026 and Form 4 insider filings as recently as August 27, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), UFP TECHNOLOGIES INC (UFPT) reported revenue of $602.8 million (up 19.5% from FY2024) and net income of $68.3 million. Diluted EPS was $8.75.
  • As of September 30, 2026, 33 institutional investment managers tracked by SignalX reported holding UFP TECHNOLOGIES INC (UFPT) shares worth $968.8 million in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by KOZIN MARC D on August 25, 2026 of 3,350 shares at $305.07 per share.
  • In the last 90 days, UFPT insiders reported 0 open-market purchases ($0) and 2 open-market sales ($2.1M) on Form 4, a net sale of $2.1M.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$602.8M
+19.5% vs prior year
Insiders · 90 days
0 buys · 2 sells
Net −$2.1M
13F holders
33 funds
$968.8M · +1 vs prior quarter
Latest 8-K
Nov 3, 2026
Item 2.02

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Dec 31, 2025

Full analysis →

Business Overview

  • Core business: Contract development and manufacturing of custom single-use, single-patient medical devices and components
  • Emphasis on diverse niche medical segments including minimally invasive surgery, infection prevention, orthopedics, and biopharma packaging
  • Employee count increased notably by 700 full-time employees and 314 temporary workers YoY to 4,846 and 503 respectively
  • 32 manufacturing locations with 19 ISO 13485 certified and 13 FDA registered, reinforcing regulatory compliance focus
  • Sustainability effort: Newburyport MA facility uses solar providing ~6% electricity, with capacity expansion planned

Risk Factors

  • Regulatory risk from "One Big Beautiful Bill Act" (OBBBA) enacted July 2025 with immaterial impact on income tax expense but changes to interest and depreciation rules
  • Macroeconomic risk from inflation and bank failures could affect long-term capital access and liquidity despite $91.9M cash from operations in 2025
  • Operational risk from AJR Labor Issue reduced gross margin by 1.0% in 2025, impacting cost control and profitability
  • Competitive risk from increased acquisitions in 2024-2025 contributed $168.3M sales but increased SG&A by $17.8M, pressuring expense efficiency
  • Financial risk from $135.5M debt outstanding at 5.1% interest with covenants under third amended credit agreement maturing in 2029

Management Discussion & Analysis

  • Revenue $602.8M, up 19.5% YoY from $504.4M driven by 23.2% medical market growth, acquisitions added $168.3M in 2025 vs $73.1M in 2024
  • Organic sales growth 1.5% for 2025; largest customers Intuitive Surgical SARL 24.3% and Stryker Corporation 21.5% of sales in 2025
  • Incremental labor costs from AJR labor issue $6.3M impacting cost-of-sales and operational efficiencies in 2025
  • Tariffs had immaterial impact on 2025 results despite dynamic trade environment and increased US tariffs on foreign imports
  • Cyber incident detected February 2026, no material impact on operations or financial condition as of filing date, ongoing investigation

AI summary of the UFPT 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Q3 revenue $172.4M, up 11.6% from $154.6M YoY
  • Gross margin 29.4% vs 27.7% YoY, SG&A margin 13.4% vs 12.3%
  • Strongest markets: Patient Beds and Handling, Cardiovascular, Infection Control, Orthopedics, with no individual figures disclosed
  • Operating cash flow $57.4M for nine months, capital spending $13.7M, debt payments $39.5M
  • Outlook: capacity additions and potential acquisitions, tariff environment remains dynamic, resources sufficient through next twelve months

Risk Factors

  • No newly added risk factors, with no material changes from the 2025 Form 10-K
  • No materially updated risk identified for the quarter
  • Regulatory and compliance risks carried forward from the 2025 Form 10-K
  • Operational, competitive, and market risks unchanged from prior filings
  • Liquidity, debt, currency, and customer-concentration risks unchanged from prior filings

AI summary of the UFPT 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 3, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q3 fiscal 2026 results announced for quarter ended September 30, 2026
  • Exhibit 99.1 contains the substantive financial results and management commentary

Item EX-99.1: Item EX-99.1

  • Q3 sales $172.4M, up 11.6%, including 11.1% organic growth, signaling broad-based demand rather than acquisition-only expansion
  • Gross margin expanded to 29.4% from 27.7%, while adjusted operating income rose 14.5% to $30.1M
Filed Aug 24, 2026Full analysis →

Item 7.01: Regulation FD Disclosure

  • Updated investor presentation signals refreshed messaging on UFP Technologies’ business and strategy
  • Materials intended for investor meetings and public presentations, potentially influencing near-term market expectations
Filed Aug 3, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q2 2026 results for the quarter ended June 30, 2026 announced on August 3, 2026
  • Financial details and management commentary available in Exhibit 99.1, the accompanying earnings release

Item EX-99.1: Item EX-99.1

  • Q2 sales $174.0M, up 15.1%, with organic growth 12.4%, signaling broad MedTech demand and contribution from acquisitions
  • Net income $20.9M, up 21.4%, while diluted EPS reached $2.68 GAAP and $2.92 adjusted

AI summaries of UFPT 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for UFPT

Don't miss the next UFPT filing

  • Alerts as it files. A push when UFPT files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut UFPT, by share count.
  • Ask anything. An AI agent that reads every UFPT filing and answers with sources.

UFPT alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
KOZIN MARC DSellAug 25, 2026$305.07
KOZIN MARC DSellAug 25, 2026$303.97
Hudson SymeriaSellAug 18, 2026$319.11
Hudson SymeriaSellAug 14, 2026$324.58
Hudson SymeriaMAug 13, 2026$260.92
Hudson SymeriaMAug 13, 2026-
Hudson SymeriaMAug 13, 2026-
Hudson SymeriaMAug 13, 2026$167.98

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$504.4M$602.8M
Gross Profit-$146.7M$170.4M
Operating Income-$80.9M$92.3M
Net Income-$59.0M$68.3M
Gross Margin-29.1%28.3%
Op. Margin-16.0%15.3%
Net Margin-11.7%11.3%
Balance Sheet
Total Assets$404.1M$629.0M$655.1M
Equity$286.1M$342.8M$423.9M
ROE-17.2%16.1%
Per Share
EPS-$7.58$8.75
Cash Flow
Operating CF-$66.6M$91.9M
CapEx$10.5M$9.7M-

Source: XBRL data in UFP TECHNOLOGIES INC (UFPT)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate UFPT share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
UFPT shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202633$968.8M
Q2 202632$856.9M
Q1 202631$597.5M
Q4 202529$673.9M
Q3 202530$646.4M
Q2 202530$844.3M
Q1 202528$445.6M
Q4 202425$495.0M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 238 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

UFPT filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
10-QNov 6, 2026Analysis
8-KNov 3, 2026Analysis-
4Aug 27, 2026--
8-KAug 24, 2026Analysis-
4Aug 19, 2026--
4Aug 17, 2026--
4Aug 17, 2026--
4Aug 11, 2026--
4Aug 10, 2026--
4Aug 7, 2026--
10-QAug 6, 2026Analysis
8-KAug 3, 2026Analysis-
SC 13GJul 31, 2026-
SC 13GJul 7, 2026-
4Jun 15, 2026--
8-KJun 10, 2026Analysis
4Jun 8, 2026-
4Jun 8, 2026-
4Jun 8, 2026-
4Jun 8, 2026-
4Jun 8, 2026-
4Jun 8, 2026-
4Jun 8, 2026-
4Jun 8, 2026-
4Jun 8, 2026-

Related Health Care companies

All Health Care →

UFPT SEC filings: frequently asked questions

Are UFPT insiders buying or selling?

In the last 90 days, UFP TECHNOLOGIES INC (UFPT) officers, directors and 10% owners reported no open-market purchases and 2 open-market sales worth $2.1 million by 1 insider on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold UFPT stock?

As of September 30, 2026, the largest UFP TECHNOLOGIES INC (UFPT) holders among the 13F filers tracked by SignalX were BlackRock ($337.8 million), T. Rowe Price Group ($102.4 million), Vanguard Capital Management LLC ($97.7 million), State Street Corp ($93.4 million), Dimensional Fund Advisors ($55.1 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was UFPT's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), UFP TECHNOLOGIES INC (UFPT) reported revenue of $602.8 million (up 19.5% from FY2024) and net income of $68.3 million. Diluted EPS was $8.75. The figures come from the XBRL data in the 10-K.

What are the main risks in UFPT's latest 10-K?

In the 10-K filed February 27, 2026, UFP TECHNOLOGIES INC (UFPT) flagged: Regulatory risk from "One Big Beautiful Bill Act" (OBBBA) enacted July 2025 with immaterial impact on income tax expense but changes to interest and depreciation rules. Macroeconomic risk from inflation and bank failures could affect long-term capital access and liquidity despite $91.9M cash from operations in 2025. (AI summary of the Risk Factors section.)

What did UFPT report in its latest 8-K?

UFP TECHNOLOGIES INC (UFPT) filed an 8-K on November 3, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 fiscal 2026 results announced for quarter ended September 30, 2026.

What are the latest UFPT SEC filings?

UFP TECHNOLOGIES INC (UFPT) filed its latest 10-K annual report on February 27, 2026, a 10-Q quarterly report on November 6, 2026, an 8-K current report on November 3, 2026 and a Form 4 insider filing on August 27, 2026.

What is UFPT's SEC CIK number?

UFP TECHNOLOGIES INC (UFPT)'s SEC Central Index Key (CIK) is 914156. EDGAR lists every UFPT filing under that number.

Ask anything about UFPT

The research agent reads UFPT's filings, financials, insider trades and 13F holders, then answers with sources.